Skip to main content

Table 3 Self-reported oral effects of administration of pilocarpine solution to patients with Sjӧgren’s syndrome

From: New low-dose liquid pilocarpine formulation for treating dry mouth in Sjögren’s syndrome: clinical efficacy, symptom relief, and improvement in quality of life

Item   VAS (10 cm) b  
Pre-administration Post-administration at 60 min Continuous administration
Dryness 7.1 (6.1, 8.0) 4.4 (2.2, 6.5) a 3.7 (2.0, 6.9) a
Thirstiness 6.3 (4.5, 7.9) 2.3 (0.7, 5.4) a 2.4 (1.5, 5.3) a
Stickiness 6.3 (4.8, 7.4) 4.0 (0.7, 5.4) 2.4 (0.9, 6.5)
Altered taste 0.5 (0.3, 4.3) 1.1 (0.5, 4.3) 1.4 (0.5, 3.2)
Painful tongue 4.1 (0.4, 7.8) 1.3 (0.5, 6.4) 2.2 (0.4, 7.0)
  1. a: Significantly different from pre-administration at P < 0.05 (Scheffe’s F test) (n = 21)
  2. bVAS, visual analog scale; Median (1st quartile, 3rd quartile)
\